重组人红细胞生成素治疗恶性肿瘤贫血的现状

Current status of recombinant human erythropoietin for anemia with malignancies

导出

摘要近年来,重组人红细胞生成素在治疗恶性肿瘤贫血中得到了广泛的应用,但它的不良反应及对患者生存率的影响目前仍有一定争议。 In resent years, recombinant human erythropoietin（rhEPO） is used widely in the treatment of cancer-related anemia. But, its adverse reaction and influence on survival rates of patients with malignancy are still argued up to now.

作者孙衍伟（综述）安永恒（审校）

机构地区山东省日照市人民医院肿瘤科

出处《国际肿瘤学杂志》 CAS 2007年第8期623-625,共3页 Journal of International Oncology

关键词红细胞生成素肿瘤贫血 Erythropoietin Neoplasms Anemia

分类号 R730.54 [医药卫生—肿瘤]

引文网络
相关文献

参考文献23

1Harrison LB, Shasha D, Homel P. Prevalence of anemia in cancer patients undergoing radiotherapy: prognostic significance and treatment. Oncology, 2002,63 Suppl 2 : 11 - 18.
2Littlewood T, Mandelli F, The effects of anemia in hematologic malignancies: more than a symptom. Semin Oncol,2002,29 (3 Suppl 8 ) : 40-44.
3Shasha D, George M J, Harrison LB. Once-weekly dosing of epoetinalpha increases hemoglobin and improves quality of life in anemic cancer patients receiving radiation therapy either concomitantly or sequentially with chemotherapy. Cancer,2003,98(5) :1072-1079.
4Voravud N, Sriuranpong V. Clinic-,d benefits of epoetin alfa (Eprex) 10,000 units subcutaneously thrice weekly in Thai cancer patients with anemia receiving chemotherapy. J Med Assoc Thai,2005,88 (5) :607- 612.
5Rosenzweig MQ, Bender CM, Lucke JP, et al. The decision to prematurely terminate a trial of R-HuEPO due to thrombotic events. J Pain Symptom Manage ,2004,27 ( 2 ) : 185-190.
6Quirt I, Robeson C, Lau CY, et al. Epoetin alfa therapy increases hemoglobin levels and improves quality of life in patients with cancer-related anemia who are not receiving chemotherapy and patients with anemia who are receiving chemotherapy. J Clin Oncol, 2001,19 (21) : 4126-4134.
7Littlewood TJ, Bajetta E, Nortier JW, et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Onco1,2001,19 ( 11 ) :2865-2874.
8Glaspy J, Degos L, Dicato M, et al. Comparable efficacy of epoetin alfa for anemic cancer patients receiving platinum and nonplatinum-based chemotherapy: a retrospective subanalysis of two large, communitybased trials. Oncologist ,2002,7 ( 2 ) : 126-135.
9Henry DH. The evolving role of epoetin alfa in cancer therapy. Oncologist, 2004, 9(1) :97-107.
10Lovey J, Kenessey I, Raso E, et al. Human recombinant erythropoietin-alpha increases the efficacy of irradiation in preclinical model. Magy Onkol, 2007,51 ( 1 ) :53-61.

1鲍扬漪,瞿尔鑫,彭丽娟,何皖伟.红细胞生成素治疗血液系统恶性肿瘤贫血[J].皖南医学院学报,1996,15(4):343-344.
2方国全.红细胞生成素治疗恶性肿瘤贫血的疗效观察[J].安徽医药,2002,6(4):10-11.
3鲍扬漪,金运松,瞿尔鑫.红细胞生成素治疗恶性肿瘤贫血[J].临床血液学杂志,1995,8(4):166-167. 被引量：2
4孙衍伟,安永恒.rhEPO治疗恶性肿瘤贫血的现状及争议[J].中国临床实用医学,2007,1(7). 被引量：1
5王莹,燕丽香,陈文彰.恶性肿瘤贫血相关因素分析[J].中国医药导刊,2013,15(7):1156-1157. 被引量：8
6孙衍伟（综述）,安永恒（审校）.重组人红细胞生成素治疗恶性肿瘤贫血的争论[J].国际肿瘤学杂志,2007,34(5):390-393. 被引量：1
7于雷.恶性肿瘤患者发生贫血的危险因素分析[J].中国肿瘤,2013,22(5):403-405. 被引量：11
8孙衍伟,牟玲,安永恒.重组人红细胞生成素高剂量疗法对恶性肿瘤贫血的疗效观察[J].中国医药,2008,3(9):542-543. 被引量：1
9孙衍伟,安永恒,丁兆军,周嘉云,梁军.重组人红细胞生成素治疗恶性肿瘤贫血最佳剂量的探讨[J].中国综合临床,2007,23(9):791-793. 被引量：1
10王泽阳,侯梅,王海燕,陈萍,徐聂,赵振华.重组人红细胞生成素治疗肿瘤化疗相关性贫血临床研究[J].西部医学,2009,21(6):912-913. 被引量：4

国际肿瘤学杂志

2007年第8期

浏览历史

内容加载中请稍等...

重组人红细胞生成素治疗恶性肿瘤贫血的现状

参考文献23

相关作者

相关机构

相关主题

浏览历史